Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2014 | Original Article

Somatostatin-based radiopeptide therapy with [¹⁷⁷Lu-DOTA]-TOC versus [⁹⁰Y-DOTA]-TOC in neuroendocrine tumours

Authors: A. Romer, D. Seiler, N. Marincek, P. Brunner, M. T. Koller, Q. K. T. Ng, H. R. Maecke, J. Müller-Brand, C. Rochlitz, M. Briel, C. Schindler, M. A. Walter

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2014

Abstract

Purpose

Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides ⁹⁰Y or ¹⁷⁷Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches.

Methods

In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [⁹⁰Y-DOTA]-TOC or [¹⁷⁷Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups.

Results

Overall, 910 patients underwent 1,804 cycles of [⁹⁰Y-DOTA]-TOC and 141 patients underwent 259 cycles of [¹⁷⁷Lu-DOTA]-TOC. The median survival after [¹⁷⁷Lu-DOTA]-TOC and after [⁹⁰Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63–1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [¹⁷⁷Lu-DOTA]-TOC over [⁹⁰Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [¹⁷⁷Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32).

Conclusion

The present results revealed no difference in median overall survival after [¹⁷⁷Lu-DOTA]-TOC and [⁹⁰Y-DOTA]-TOC. Furthermore, [¹⁷⁷Lu-DOTA]-TOC was less haematotoxic than [⁹⁰Y-DOTA]-TOC.

Available only for authorised users

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063–72.PubMedCrossRef

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501–13.PubMedCrossRef

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514–23.PubMedCrossRef

Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12 Suppl 2:S111–4.PubMedCrossRef

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389–427.PubMedCrossRef

Oberg K. Cancer: antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 2010;6(4):188–9.PubMedCrossRef

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656–63.PubMedCrossRef

Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242–4.PubMedCrossRef

Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351(9100):417–8.PubMedCrossRef

10.

Marincek N, Jörg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med 2013;11:17.PubMedCentralPubMedCrossRef

11.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29(17):2416–23.PubMedCrossRef

12.

Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24(7):792–5.PubMed

13.

Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30(10):1100–6.PubMedCrossRef

14.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439–47.PubMedCrossRef

15.

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12(7):941–5.PubMedCrossRef

16.

Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007;13(22 Pt 1):6696–702.PubMedCrossRef

17.

Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer 2009;115(10):2052–62.PubMedCrossRef

18.

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877–84.PubMedCrossRef

19.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S–7S.PubMed

20.

Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26(11):2389–430.PubMedCrossRef

21.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.CrossRef

22.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16.PubMedCrossRef

23.

Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35(1):152–6.PubMed

24.

Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.

25.

Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging 2011;38(7):1270–80.PubMedCrossRef

26.

Chen PS, Terepka AR, Hodge HC. The pharmacology and toxicology of the bone seekers. Annu Rev Pharmacol 1961;1(1):369–96.CrossRef

27.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124–30.PubMedCrossRef

Title: Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
Authors: A. Romer
D. Seiler
N. Marincek
P. Brunner
M. T. Koller
Q. K. T. Ng
H. R. Maecke
J. Müller-Brand
C. Rochlitz
M. Briel
C. Schindler
M. A. Walter
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2559-8

ACC 2024 Congress

Springer Medicine

Somatostatin-based radiopeptide therapy with [¹⁷⁷Lu-DOTA]-TOC versus [⁹⁰Y-DOTA]-TOC in neuroendocrine tumours

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter

131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa

EJNMMI Physics—Access is open for open access

Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study

Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI